Imidazolyl alkyl guanidine derivatives, processes for their preparation
申请人:Heumann Pharma GmbH & Co.
公开号:US05021431A1
公开(公告)日:1991-06-04
New imidazolylalkyl-guanidine derivatives are described, which by virtue of their agonistic action on histamine-H.sub.2 receptors and in part also due to their additional H.sub.1 -antagonistic receptor activity can be used in the treatment of cardiac diseases, certain forms of hypertension and diseases of arterial occlusion. These imidazolylalkyl-guanidine derivatives correspond to the general formula I: ##STR1##
BUSCHAUER, ARMIN, J. MED. CHEM., 32,(1989) N, C. 1963-1970
作者:BUSCHAUER, ARMIN
DOI:——
日期:——
US5021431A
申请人:——
公开号:US5021431A
公开(公告)日:1991-06-04
Synthesis and in vitro pharmacology of arpromidine and related phenyl(pyridylalkyl)guanidines, a potential new class of positive inotropic drugs
作者:Armin Buschauer
DOI:10.1021/jm00128a045
日期:1989.8
-yl)propyl]-N2-[2-[[(5-methyl-1H-imidazol-4- yl)methyl]thio]ethyl]guanidine) by more lipophilic H2-nonspecific pheniramine-like structures resulted in potent H2 agonists with up to 160 times the activity of histamine in the isolated, spontaneously beating guineapig right atrium. Additionally, the compounds proved to be moderate H1 antagonists. Highest H2-agonistic potency was found in compounds characterized